Asset Details
Do you wish to reserve the book?
Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system
Do you wish to request the book?
Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Novel staging for gastric neuroendocrine neoplasms by incorporating the WHO grading into the TNM staging system
2023
Overview
Background The 8th tumor‐node‐metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC) can be used to estimate the prognosis of gastric neuroendocrine tumor (gNET) and gastric neuroendocrine carcinoma (gNEC) patients but not gastric neuroendocrine neoplasms (gNENs). Methods First, in the SEER (training) dataset, a TNMG system was built by combining the WHO G grade (G1‐4; NEC grouped into G4) with the 8th AJCC T (T1‐4), N (N0‐1), and M (M0‐1) stage, which was then validated in a Chinese (validation) cohort. Results In all, 2245 gNENs cases from the training dataset and 280 cases from the validation dataset were eligible. The T stage, M stage, and G grade were independent prognostic factors for OS in both datasets (all p < 0.05). The TNMG staging system demonstrated better C‐index for predicting OS than the 8th AJCC TNM staging system in both the training (0.87, 95%CI: 0.86–0.88 vs. 0.79, 95%CI: 0.77–0.81) and validation (0.77, 95%CI: 0.73–0.80 vs. 0.75, 95%CI: 0.71–0.79) datasets. The AUC of the 3‐year OS for the TNMG staging system was 0.936 and 0.817 in the SEER and validation dataset, respectively; higher than those of the 8th AJCC system (vs. 0.843 and 0.779, respectively). DCA revealed that compared with the 8th AJCC TNM staging system, the TNMG staging system demonstrated superior net prognostic benefit in both the training and validation datasets. Conclusions The proposed TNMG staging system could more accurately predict the 3‐ and 5‐year OS rate of gNENs patients than the 8th AJCC TNM staging system. The proposed TNMG staging system for gastric neuroendocrine neoplasms was successfully validated in a two‐center dataset of a different ethnicity than the SEER training dataset. This novel staging system could more accurately prognosticate the 3‐ and 5‐year OS rate than the 8th AJCC TNM staging system.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
